The sensitivity of lung cancer to gefitinib has been found to be associated with mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR),
1-3 yet similar observations are not available for other solid tumors.
4 We investigated whether gefitinib-sensitizing mutations in the
EGFR gene were present in human esophageal tumors.